Trials / Recruiting
RecruitingNCT07195682
A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
A Phase 1/1b Open-label, Multi-center Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 125 (estimated)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a first-in-human study of BMS-986506 in participants with advanced Clear Cell Renal Cell Carcinoma (ccRCC). The primary objective of this study is to find out if BMS-986506 is safe and can be tolerated when taken alone by participants with ccRCC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-986506 | Specified dose on specified days |
Timeline
- Start date
- 2026-01-15
- Primary completion
- 2030-05-03
- Completion
- 2031-04-03
- First posted
- 2025-09-29
- Last updated
- 2026-04-07
Locations
9 sites across 4 countries: United States, Canada, France, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07195682. Inclusion in this directory is not an endorsement.